Patent · US Active

Combinations of AKT inhibitor compounds and vemurafenib, and methods of use

US9150548B2 · kind B2 · utility

4Cited by

41References

14Claims

0Family size

Assignee

Genentech, Inc. · US

Inventors

Klaus Hoeflich · San Mateo, US
Mark Merchant · South San Francisco, US

Key dates

Filing date	Mar 30, 2012
Grant date	Oct 6, 2015
Priority date	—
Expiry date	Mar 30, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/505
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.